JPWO2021090062A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021090062A5
JPWO2021090062A5 JP2022525715A JP2022525715A JPWO2021090062A5 JP WO2021090062 A5 JPWO2021090062 A5 JP WO2021090062A5 JP 2022525715 A JP2022525715 A JP 2022525715A JP 2022525715 A JP2022525715 A JP 2022525715A JP WO2021090062 A5 JPWO2021090062 A5 JP WO2021090062A5
Authority
JP
Japan
Prior art keywords
antibody
seq
cancer
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022525715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500875A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/000917 external-priority patent/WO2021090062A1/en
Publication of JP2023500875A publication Critical patent/JP2023500875A/ja
Publication of JPWO2021090062A5 publication Critical patent/JPWO2021090062A5/ja
Pending legal-status Critical Current

Links

JP2022525715A 2019-11-07 2020-11-06 抗メソテリンエリブリン抗体-薬物コンジュゲート及び使用方法 Pending JP2023500875A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962932373P 2019-11-07 2019-11-07
US62/932,373 2019-11-07
PCT/IB2020/000917 WO2021090062A1 (en) 2019-11-07 2020-11-06 Anti-mesothelin eribulin antibody-drug conjugates and methods of use

Publications (2)

Publication Number Publication Date
JP2023500875A JP2023500875A (ja) 2023-01-11
JPWO2021090062A5 true JPWO2021090062A5 (ru) 2023-11-08

Family

ID=73943294

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022525715A Pending JP2023500875A (ja) 2019-11-07 2020-11-06 抗メソテリンエリブリン抗体-薬物コンジュゲート及び使用方法

Country Status (15)

Country Link
US (2) US11572414B2 (ru)
EP (1) EP4055053A1 (ru)
JP (1) JP2023500875A (ru)
KR (1) KR20220095197A (ru)
CN (1) CN114729042A (ru)
AU (1) AU2020380603A1 (ru)
BR (1) BR112022008756A2 (ru)
CA (1) CA3159541A1 (ru)
CO (1) CO2022007924A2 (ru)
IL (1) IL291643A (ru)
JO (1) JOP20220070A1 (ru)
MX (1) MX2022005221A (ru)
PE (1) PE20230467A1 (ru)
TW (1) TW202132345A (ru)
WO (1) WO2021090062A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019232433A2 (en) 2018-06-01 2019-12-05 Eisai R&D Management Co., Ltd. Methods of using splicing modulators
AU2020380603A1 (en) 2019-11-07 2022-06-02 Eisai R&D Management Co., Ltd. Anti-mesothelin eribulin antibody-drug conjugates and methods of use
AU2022316425A1 (en) * 2021-07-22 2024-02-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Drug conjugate of eribulin derivative
CN118043080A (zh) * 2021-08-13 2024-05-14 昆山新蕴达生物科技有限公司 一种基于微管抑制剂的抗体偶联药物
TW202321296A (zh) 2021-10-06 2023-06-01 美商鏈接免疫療法公司 抗間皮素抗原結合分子及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
AU666852B2 (en) 1991-05-01 1996-02-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine A method for treating infectious respiratory diseases
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
AU2063197A (en) 1996-03-04 1997-09-22 Massachusetts Institute Of Technology Materials and methods for enhancing cellular internalization
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
KR100798600B1 (ko) 1998-06-17 2008-01-28 에자이 가부시키가이샤 마크로시클릭 유사체 및 그들의 이용 및 제조방법
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
BR112017027252A2 (pt) 2015-06-19 2018-08-28 Eisai R&D Management Co., Ltd. imunoglobulinas conjugadas a cys80
UA124622C2 (uk) 2015-12-18 2021-10-20 ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. Кон'юговані імуноглобуліни з c-кінцевим лізином
WO2017136769A1 (en) 2016-02-04 2017-08-10 Eisai R&D Management Co., Ltd. Peptide drug conjugates
CN114191428A (zh) 2016-03-02 2022-03-18 卫材研究发展管理有限公司 基于艾日布林的抗体-药物偶联物和使用方法
JOP20200268A1 (ar) 2018-06-01 2020-10-26 Eisai R&D Man Co Ltd تضفير مترافقات عقار جسم مضاد معدل وطرق استخدامها
JP2022512401A (ja) 2018-12-13 2022-02-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハーボキシジエンスプライシング調節薬抗体-薬物コンジュゲート及びその使用方法
AU2020380603A1 (en) 2019-11-07 2022-06-02 Eisai R&D Management Co., Ltd. Anti-mesothelin eribulin antibody-drug conjugates and methods of use
TW202140078A (zh) 2020-01-22 2021-11-01 大陸商上海森輝醫藥有限公司 艾日布林衍生物的藥物偶聯物、其製備方法及其在醫藥上的應用
IL298053A (en) 2020-06-05 2023-01-01 Eisai R&D Man Co Ltd Antibody-drug conjugates against bcma and methods of use

Similar Documents

Publication Publication Date Title
JP6333882B2 (ja) 抗体−薬剤コンジュゲート
JP2020019787A5 (ru)
RU2018134331A (ru) Конъюгаты антитело-лекарственное средство на основе эрибулина и способы применения
RU2483080C2 (ru) Антитела и иммуноконъюгаты и их применение
AU2009212436B2 (en) Camptothecin-binding moiety conjugates
JP2019535731A5 (ru)
US20200188525A1 (en) Anti-egfr antibody drug conjugates (adc) and uses thereof
JPWO2021090062A5 (ru)
EP1877083A2 (en) Antibodies for the treatment of cancers
JPWO2021251459A5 (ru)
US20200297863A1 (en) Anti-egfr antibody drug conjugates (adc) and uses thereof
WO2023124963A1 (zh) 一种可逆反应减少的抗体-药物偶联物,其制备方法及应用
WO2023098691A1 (zh) 抗体药物偶联物及其用途
RU2020136692A (ru) Конъюгаты антител с лекарственными веществами и их применение для лечения раковых заболеваний
NZ615308B2 (en) Antibody-drug conjugates